CFR Chemaphor Inc.

Chemaphor (TSX VENTURE:CFR) announced today commercialization plans for its
Oximunol(TM) Chewables product, a proprietary natural health enhancer ("NHE")
for oral use in companion dogs. Following the recent successful outcome of the
Oximunol(TM)supplement canine clinical development program, Chemaphor now is
beginning to execute product launch and marketing plans. Given market needs and
the critical elements to ensure the optimal adoption of the product, a
determination has been made to launch this product into the veterinary channel
as a complementary medicine and wellness product. To support this launch,
Chemaphor is working with industry leaders in the sales, marketing, and
veterinary communities. Accordingly, a series of veterinary interviews has been
undertaken to ensure the Oximunol(TM)supplement meets the expectations of
veterinarians and the canines in their care to help maximize the desirability
and acceptance of the product by dog owners. Positive feedback from these
sessions regarding the potential benefits to owners of providing Oximunol(TM)
Chewables to their dogs is driving completion of the final product launch,
marketing, and sales plan, in addition to establishing final manufacturing
product volumes. With the recent announcement of the Vet-Stem stem cell
licensing arrangement, Chemaphor is evaluating the establishment of a sales team
to promote the use of Oximunol(TM) Chewables as well as the Vet-Stem products
for companion animals. Mr David Hankinson, Chairman of the Board of Chemaphor,
commented "It is exciting for Chemaphor to be entering the commercialization
stage with Oximunol(TM) Chewables after over 10 years of scientific evaluation
of the active ingredient, OxC-beta. The Oximunol(TM) Chewables product fits very
nicely into the Chemaphor portfolio of NHE products being developed to assist
animals and humans to achieve and maintain wellness."


About Oximunol(TM) Chewables 

Oximunol(TM) Chewables contain OxC-beta, a proprietary mixture of carotenoid
oxidation products. Oxidized derivatives of carotenoids occur extensively in the
plant world in minute amounts and, as such, are a natural part of the diet.
OxC-beta is obtained via the spontaneous, full oxidation of ss-carotene. Uses
for OxC-beta and other oxidized carotenoid products are protected by patents
owned by Chemaphor in multiple jurisdictions. Additionally, Chemaphor has filed
patent applications directed to products containing OxC-beta and its use for
enhancing and maintaining the wellness of companion animals.


About Chemaphor 

Chemaphor, a wellness company, is committed to developing and delivering NHE
products to humans and animals to assist in optimizing health and daily quality
of life. Chemaphor is advancing NHE product candidates for the food animal
market, companion animal market and various, potential human applications. More
information can be found at www.chemaphor.com.


Forward Looking Statements 

This news release includes certain forward-looking statements that are based
upon current expectations, which involve risks and uncertainties associated with
Chemaphor's business and the environment in which the business operates. Any
statements contained herein that are not statements of historical facts may be
deemed to be forward-looking, including those identified by the expressions
"anticipate", "believe", "plan", "estimate", "expect", "intend", and similar
expressions to the extent they relate to Chemaphor or its management. The
forward-looking statements are not historical facts, but reflect Chemaphor's
current expectations regarding future results or events. These forward-looking
statements are subject to a number of risks and uncertainties that could cause
actual results or events to differ materially from current expectations.
Chemaphor assumes no obligation to update the forward-looking statements, or to
update the reasons why actual results could differ from those reflected in the
forward-looking statements.

Chemaphor Inc. (TSXV:CFR)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024

Chemaphor Inc. (TSXV:CFR)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024